Description: Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Home Page: www.innate-pharma.com
117, Avenue de Luminy
Marseille,
13009
France
Phone:
33 4 30 30 30 30
Officers
Name | Title |
---|---|
Dr. Mondher Mahjoubi M.D. | Chairman of Exec. Board & CEO |
Mr. Yannis Morel Ph.D. | Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board |
Dr. Herve Brailly | Co-Founder & Chairman of Supervisory Board |
Dr. François Romagné Ph.D. | Founder |
Mr. Eric Vivier D.V.M., M.B.A., Ph.D. | Founder, Sr. VP & Chief Scientific Officer |
Dr. Marc Bonneville Ph.D. | Founder |
Mr. Jean Jacques Fournié Ph.D. | Founder |
Mr. Alessandro Moretta M.D., Ph.D. | Founder |
Mr. Frederic Lombard M.B.A. | Sr. VP & CFO |
Ms. Odile Belzunce | VP of Compliance & Operations |
Exchange: PA
Country: FR
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.4342 |
Price-to-Sales TTM: | 3.0375 |
IPO Date: | 2006-11-01 |
Fiscal Year End: | December |
Full Time Employees: | 213 |